Infectious complications of solid organ transplantations

Infectious Disease Clinics of North America

Volumn 15, Issue 2, 2001, Pages 521-549

  Simon, David M ^b   Levin, Stuart ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMIKACIN; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIPARASITIC AGENT; AZATHIOPRINE; AZITHROMYCIN; CEFOTAXIME; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; FAMCICLOVIR; FLUCONAZOLE; GANCICLOVIR; IMIPENEM; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; ISONIAZID; ITRACONAZOLE; IVERMECTIN; LYMPHOCYTE ANTIBODY; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PYRIMETHAMINE SULFADIAZINE; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; THYMOCYTE ANTIBODY; TIABENDAZOLE; VALACICLOVIR; VORICONAZOLE;

ASPERGILLUS; CANDIDA; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; GRAFT REJECTION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; KAPOSI SARCOMA; LEGIONELLA; LISTERIA; MUCORMYCOSIS; MYCOBACTERIOSIS; NOCARDIA; ORGAN TRANSPLANTATION; PNEUMOCYSTOSIS; REVIEW; RHODOCOCCUS; STRONGYLOIDIASIS; TOXOPLASMOSIS; VARICELLA ZOSTER VIRUS;

EID: 0034964086     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70158-6     Document Type: Article

References (102)

1. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant patients in Spain
2. Increased risk of pneumococcal infections in cardiac transplant recipients
3. Kaposi's sarcoma
4. Prevention and treatment of cytomegalovirus infection and disease in heart transplant recipients
5. High levels of Epstein-Barr virus DNA in blood of solid organ transplant recipients and their value in predicting post-transplant lymphoproliferative disorders
6. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood
7. Bacterial mediastinitis after heart transplantation
8. Infections in lung transplant recipients
9. Pneumonia after heart transplantation: A multi-institutional study
10. Epstein-Barr virus infection
11. Coccidioidomycosis in renal replacement therapy
12. Risk factors for invasive fungal infections complicating orthotopic liver transplantation
13. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation
14. Infectious complications in pulmonary allograft recipients
15. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation
16. Infections in solid organ transplant recipients
17. Effect of cytomegalovirus infection status on first year mortality rates among orthotopic liver transplant recipients
18. Infection in organ transplant recipients
19. Infectious complications of lung transplantation - Impact of cystic fibrosis
20. Outcome of kidney transplant recipients with previous human herpesvirus-8 infection
21. Toxoplasmosis in heart transplant recipients
22. Bacterial infection as a complication of liver transplantation: Epidemiology and risk factors
23. Patterns of infection after pediatric liver transplantation
24. Urological complications after kidney-pancreas transplantation
25. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued?
26. Transplanted infections: Donor-to-host transmission with the allograft
27. Epstein-Barr virus infection in heart and heart-lung transplant recipients: Incidence and clinical impact
28. Betaherpesviruses in transplant recipients
29. Infections in heart transplant recipients: The experience of the Italian heart transplantation program
30. Invasive aspergillosis after transplantation
31. Coccidioidomycosis and heart transplantation
32. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening
33. Clinical aspects of fungal infection in organ transplant recipients
34. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids
35. Infection in the transplanted and native lung after single lung transplantation
36. Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients
37. Primary-effusion lymphoma and Kaposi's sarcoma
38. Fungal infections in lung and heart-lung transplant recipients: Report of nine cases and review of the literature
39. Infectious complications in heart-lung transplantation: Analysis of 200 episodes
40. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation
41. Infectious complications after small bowel transplantation in adults: An update
42. Factors associated with invasive lung aspergillosis and the significance of positive aspergillus culture after liver transplantation
43. Nocardiosis
44. Differences in outcomes for patients with bacteremia caused by vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium
45. Listeriosis
46. The donor lung: Infectious and pathologic factors affecting outcome in lung transplantation
47. Primary and reactivated toxoplasma infection in patients with cardiac transplants: Clinical spectrum and problems in diagnosis in a defined population
48. Infectious complications following pancreatic transplantation: Incidence, microbiological, and clinical characteristics, and outcome
49. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis
50. Infectious complications following isolated lung transplantation
51. Comparative risk factors of bloodstream infection in organ transplant recipients
52. Toxoplasmosis in pediatric recipients of heart transplants
53. Infection after heart transplantation: A multi-institutional study
54. Analysis of severe infections after 180 consecutive liver transplants: The impact of amphotericin B prophylaxis for reducing the incidence and severity of fungal infections
55. Selective amphotericin B prophylaxis in the reduction of fungal infections after liver transplant
56. Opportunistic strongyloidiasis in renal transplant recipients
57. Rhodococcus equi infection in transplant recipients
58. Significance of blood stream infections after lung transplantation: Analysis in 176 consecutive patients
59. Lung transplantation: The cleveland clinic experience
60. Infections in solid organ transplant recipients
61. Infections caused by nontuberculous mycobacteria in kidney, heart, and liver transplant recipients
62. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation
63. Infective endocarditis in solid organ transplant recipients
64. Invasive aspergillosis in transplant recipients
65. Fungal infections in solid organ transplantation
66. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders
67. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations
68. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: A prospective multivariate time-dependent analysis
69. Transmission of tuberculosis by kidney transplantation
70. Infections in heart transplant recipients
71. Post-transplant infection in enteric versus bladder-drained simultaneous pancreas-kidney transplants recipients
72. Cytomegalovirus and human herpesvirus-6 both cause viral disease after renal transplantation
73. Transmission of human herpesvirus-8 infection from renal transplant donors to recipients
74. Current status of intestinal transplantation in children
75. Human herpesvirus-6 in liver transplant recipients: Role in pathogenesis of fungal infections, neurologic complications, and outcome
76. Infectious complications of renal transplantation
77. Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression
78. Blastomycosis in transplant recipients: Report of a case and review
79. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients
80. Bacteremia after intestinal transplantation in children correlates with rejection or gastrointestinal lymphoproliferative disease
81. Disseminated Strongyloides stercoralis infection
82. Invasive aspergillosis in liver transplant recipients: Transplant in the 1990's
83. Human herpesvirus-6 infection in liver transplant recipients
84. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: Transmission by donated organ and the effect of OKT3 antibodies
85. Invasive gastrointestinal zygomycosis in a liver transplant recipient: Case report and review of zygomycosis in solid organ transplant recipients
86. Invasive fungal infections in liver transplant recipients receiving tacrolimus as the primary immunosuppressive agent
87. Invasive aspergillosis in liver transplant recipients: Association with candidemia and consumption coagulopathy and failure of low dose amphotericin-B
88. Mycobacterium tuberculosis infection in solid organ transplant recipients: Impact and implications for management
89. Risk factors for early, cumulative, and fatal infections after heart transplantation: A multi-insitutional study
90. Selective decontamination in pediatric liver transplants: A randomized prospective trial
91. Increased incidence of lympho-proliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients
92. Epidemiology of legionella pneumonia and factors associated with legionella-related mortality at a tertiary care center
93. A controlled study of trimethoprim-sulfamethoxazole prophylaxis of urinary tract infection in renal transplant recipients
94. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients: A randomized, placebo-controlled study
95. Bacterial and fungal infections after liver transplantation: An analysis of 284 patients
96. Bacteremia in transplant recipients: A prospective study of demographics, etiologic agents, risk factors and outcomes
97. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for post-transplantation lymphoproliferative disorder in adult heart, lung and other solid organ transplantations
98. Actinomycosis, nocardiosis and actinomycetoma
99. Aspergillus infection in single and double lung transplant recipients
100. Nocardial infections in renal transplant recipients
101. Infections in liver transplant recipients
102. Prophylactic fluconazole in liver transplant recipients: A randomized, double blind, placebo-controlled trial